These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 24156423)

  • 21. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
    Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Increasing sensitivity of leukemia cells to imatinib by inhibiting NHE1 and p38MAPK signaling pathway].
    Hu RH; Jin WN; Chang GQ; Lin YN; Wang J; Ru YX; Li QH; Pang TX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1341-5. PubMed ID: 23257429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments.
    Xu L; Zhao Y; Pan F; Zhu M; Yao L; Liu Y; Feng J; Xiong J; Chen X; Ren F; Tan Y; Wang H
    Biomed Res Int; 2019; 2019():6502793. PubMed ID: 31828114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
    Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
    BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of triptolide on sensitivity of K562/A02 cell line to adriamycin].
    Hui LL; Xu WL; Chen QY; Zhu XL; Long LL; Xu Y; Qing R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):66-9. PubMed ID: 22391167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells.
    Wang H; Yu J; Zhang L; Xiong Y; Chen S; Xing H; Tian Z; Tang K; Wei H; Rao Q; Wang M; Wang J
    Biochem Biophys Res Commun; 2014 Apr; 446(4):1204-10. PubMed ID: 24680683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
    Pytel D; Wysocki T; Majsterek I
    Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neferine increases STI571 chemosensitivity via inhibition of P-gp expression in STI571-resistant K562 cells.
    Qin Q; Chen XP; Yang ZS; Xiao YH; Min H; Li YJ
    Leuk Lymphoma; 2011 Apr; 52(4):694-700. PubMed ID: 21261505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of specific siRNA targeting at bcr-abl fusion gene and its combination with p27 gene clone on chronic myeloid leukemia cell line K562].
    Wang W; DU Y; Lin GQ; Li NN; Sun BZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):606-11. PubMed ID: 20561411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia.
    Xia DY; Liu L; Hao MW; Liu Q; Chen RA; Liang YM
    Braz J Med Biol Res; 2014 Dec; 47(12):1096-101. PubMed ID: 25387678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclosporin A sensitises Bcr-Abl positive cells to imatinib mesylate independently of P-glycoprotein expression.
    Frydrych I; Mlejnek P; Dolezel P
    Toxicol In Vitro; 2009 Dec; 23(8):1482-90. PubMed ID: 19735720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
    Xu F; Shi X; Li S; Cui J; Lu Z; Jin Y; Lin Y; Pang J; Pan J
    Bioorg Med Chem; 2010 Mar; 18(5):1806-15. PubMed ID: 20149665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of Homoharringtonine Combined with Imatinib on the K562/G01 Cells and Its Mechanism].
    Wu JJ; Ding YH; Deng ZK; Shi YY; Lu XY; Li YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):80-84. PubMed ID: 28245379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.
    Karimiani EG; Marriage F; Merritt AJ; Burthem J; Byers RJ; Day PJ
    Exp Hematol; 2014 Mar; 42(3):183-191.e5. PubMed ID: 24269846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Experimental research on tyrosine-kinase inhibitor STI571 and P21WAF gene clone to treat chronic myeloid leukemia].
    Wang W; Sun BZ; Liu XP; Feng Q; Shang ZC; Cao YX; Yao LB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):737-42. PubMed ID: 15631651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of tyrosine kinase inhibitor imatinib mesylate on K562 cell invasion by PTEN pathway].
    Cheng ZY; Liang WT; Yan XY; Wan JS; Bian YS; Bai P; Liang LQ; Jie JQ; Li AM
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Nov; 28(11):1129-32. PubMed ID: 23127398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
    Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
    Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Inhibitory effect of triptolide on proliferation of PC12 cells].
    Huang HW; Qiu YH
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2005 Nov; 21(4):466-9. PubMed ID: 21180177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment.
    Zhang H; Chang G; Wang J; Lin Y; Ma L; Pang T
    Leuk Res; 2013 Nov; 37(11):1583-91. PubMed ID: 24125838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.